The Anti-Diabetes Drugs market in Poland has been steadily growing in recent years, driven by a combination of factors such as changing demographics, rising obesity rates, and increasing awareness about the disease.
Customer preferences: Patients suffering from diabetes in Poland are increasingly looking for more convenient and effective treatment options. This has led to a rise in demand for oral medications and combination therapies. Additionally, there is a growing preference for drugs that have fewer side effects and are more affordable.
Trends in the market: One of the major trends in the Anti-Diabetes Drugs market in Poland is the increasing use of generic drugs. This is driven by the government's efforts to reduce healthcare costs and improve patient access to affordable medications. Another trend is the growing popularity of newer, more innovative drugs that are more effective in managing diabetes and have fewer side effects. This has led to a shift towards more personalized treatment options that are tailored to the individual needs of the patient.
Local special circumstances: Poland has a rapidly aging population, with a large percentage of the population over the age of 65. This has led to a higher incidence of diabetes and other chronic diseases, which in turn has driven demand for Anti-Diabetes Drugs. Additionally, Poland has one of the highest obesity rates in Europe, which is a major risk factor for developing diabetes. This has further contributed to the growth of the Anti-Diabetes Drugs market in the country.
Underlying macroeconomic factors: The Polish economy has been growing steadily in recent years, with rising incomes and improving healthcare infrastructure. This has led to increased access to healthcare services, including Anti-Diabetes Drugs. Additionally, the government has implemented several initiatives aimed at improving diabetes management and prevention, which has further boosted demand for Anti-Diabetes Drugs. However, the market is also facing several challenges such as increasing competition from generics and regulatory pressures to reduce drug prices.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
